<it>KRAS </it>analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice
<p>Abstract</p> <p>Background</p> <p>Epidermal growth factor receptor inhibitor therapy is now approved for treatment of metastatic colorectal carcinomas (CRC) in patients with tumors lacking <it>KRAS </it>mutations. Several procedures to detect <it>KR...
Main Authors: | Birgisson Helgi, Glimelius Bengt, Lindell Monica, Edlund Karolina, Sundström Magnus, Micke Patrick, Botling Johan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-12-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/660 |
Similar Items
-
Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status.
by: Maria Planck, et al.
Published: (2013-01-01) -
Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival
by: Holmberg Lars, et al.
Published: (2011-10-01) -
Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer
by: Lana Ghanipour, et al.
Published: (2016-06-01) -
KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015
by: Raja Jouini, et al.
Published: (2019-03-01) -
Signet Ring Cell Colorectal and Appendiceal Cancer: A Small Signet Ring Cell Component Is Also Associated with Poor Outcome
by: Malin Enblad, et al.
Published: (2023-04-01)